Replies to post #454242 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

A very comprehensive review of 2021 cases specifically against U.S. Life Sciences companies: Developments in Securities Fraud Class Actions Against U.S. Life Sciences Companies

Unlike in 2020, when courts “dismissed nearly all of the claims related to alleged misrepresentations during product development,” [56] courts in 2021 took a slightly more moderate approach. Of the 14 identified opinions, courts dismissed nine of such matters in whole [57] and one in part [58] (including appellate decisions affirming lower courts’ dismissal orders).

The 2020 situation was COVID related.

As I have mentioned about 40%/60% settled vs. dismissed.

Too many lazy opinion posts with no evidence in fact here, imo!